drugset / Trial / NCT00554255

A Study of SB751689 in Japanese Postmenopausal Women

NCT00554255

Phase 1 Completed 18 enrolled GlaxoSmithKline
RandomizedCrossoverSingle-blindTreatment

Summary

To investigate the safety and tolerability, PK and PD of SB751689 following single and 5-day multiple oral doses of 100, 200, and 400 mg in Japanese postmenopausal subjects.

Timeline

Start
2006-10-23
Primary completion
Completion
2006-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SB-751689 Unknown 100 mg
Subject SB-751689 Unknown 200 mg
Subject SB-751689 Unknown 400 mg

Indications